Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling
Standard
Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. / Holstein, Sarah A; Ye, J Christine; Howard, Alan; Bhutani, Manisha; Gormley, Nicole; Hahn, Theresa; Hillengass, Jens; Krishnan, Amrita; Landgren, C Ola; Munshi, Nikhil C; Oliva, Stefania; Owen, Roger G; Pasquini, Marcelo C; Puig, Noemi; Weinhold, Niels; Weisel, Katja; McCarthy, Philip L.
In: BIOL BLOOD MARROW TR, Vol. 25, No. 3, 03.2019, p. e89-e97.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling
AU - Holstein, Sarah A
AU - Ye, J Christine
AU - Howard, Alan
AU - Bhutani, Manisha
AU - Gormley, Nicole
AU - Hahn, Theresa
AU - Hillengass, Jens
AU - Krishnan, Amrita
AU - Landgren, C Ola
AU - Munshi, Nikhil C
AU - Oliva, Stefania
AU - Owen, Roger G
AU - Pasquini, Marcelo C
AU - Puig, Noemi
AU - Weinhold, Niels
AU - Weisel, Katja
AU - McCarthy, Philip L
N1 - Copyright © 2018 American Society for Blood and Marrow Transplantation. All rights reserved.
PY - 2019/3
Y1 - 2019/3
N2 - The second annual Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling was convened on December 7, 2017, at the American Society of Hematology (ASH) meeting. During this workshop, investigators from around the world presented their latest research involving assessment of minimal residual disease (MRD) and immune profiling (IP) in myeloma. This document summarizes the workshop presentations as well as relevant ASH abstracts and focuses on the regulatory issues involved in the integration of MRD and IP assessment in clinical trial design and practice.
AB - The second annual Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling was convened on December 7, 2017, at the American Society of Hematology (ASH) meeting. During this workshop, investigators from around the world presented their latest research involving assessment of minimal residual disease (MRD) and immune profiling (IP) in myeloma. This document summarizes the workshop presentations as well as relevant ASH abstracts and focuses on the regulatory issues involved in the integration of MRD and IP assessment in clinical trial design and practice.
KW - Journal Article
U2 - 10.1016/j.bbmt.2018.11.001
DO - 10.1016/j.bbmt.2018.11.001
M3 - SCORING: Journal article
C2 - 30408566
VL - 25
SP - e89-e97
JO - BIOL BLOOD MARROW TR
JF - BIOL BLOOD MARROW TR
SN - 1083-8791
IS - 3
ER -